Health-tech startup Temple, founded by Zomato founder Deepinder Goyal, has acquired London-based longevity medicine practice Longevous. The deal comes as Temple prepares to launch its wearable device in India later this year.
Goyal announced the acquisition on X, saying Longevous founders Dr Robert Mohr and Dr Avi Roy, along with their team, will now join Temple to bring their clinical and scientific expertise to the company’s work.
“We are excited to share that Temple is acquiring Longevous, an evidence-based longevity medicine practice based in London,” Goyal wrote. “The founders, Rob and Avi, and their team are joining Temple full time.
Dr Mohr will take on the role of chief medical officer at Temple, while Roy will become head of science. Longevous will continue to operate under Temple after the acquisition, with both doctors still looking after their existing clients.
Why Temple acquired Longevous
The acquisition seems to be largely about bringing medical and scientific expertise into Temple as the company works to test and validate its wearable. Longevous is a London-based longevity medicine practice focused on preventive and evidence-based healthcare, while its founders bring clinical and biomedical research experience that Goyal says can strengthen its validation work. “They bring in deep clinical expertise and publication experience to work alongside our in-house science team as we prepare for launch,”wrote Goyal in his post.
Goyal revealed he first met Longevous founders Dr Robert Mohr and Dr Avi Roy at a dinner in London a few months ago. They became interested in the Temple device Goyal was wearing and later started using it themselves. The two spent around two months using Temple daily and examining the data it produced.
During that time, Mohr and Roy worked with Temple’s science team to test the company’s Entropy metric and question some of its assumptions. “They challenged our assumptions and poked holes in our vision,” Goyal wrote in the post on X. “ Slowly, they became deeply involved in our validation work and have even reviewed our first scientific manuscripts before submission,” he added.
That eventually led to the two joining Temple full-time. Mohr will become chief medical officer, while Roy will take on the role of head of science.
Mohr brings nearly 20 years of clinical experience. He started his career in emergency medicine before moving into evidence-based longevity medicine, with a focus on preventive and precision healthcare. His role at Temple will involve bringing that clinical experience into the company’s research and validation work.
Roy is an Oxford-trained biomedical scientist with experience across longevity research and business. He was previously a research fellow at the University of Oxford’s Centre for the Advancement of Sustainable Medical Innovation and is also a co-founder of Founders Health and UDA. At Temple, he will lead the company’s science work.
When is Temple launching?
Meanwhile, Temple is now getting closer to its first wider rollout. Goyal earlier revealed that the company will soon open pre-orders for a Limited Launch Edition, with the first units expected to ship before the end of 2026.
The wearable has also changed quite a bit since it was first shown. Goyal recently revealed that the latest version is now less than half the size of the earlier model, although the company has not yet revealed its exact dimensions or weight.
Temple has already gone through early-access testing, with Goyal previously saying the first 100 devices were ready for selected users, including athletes, doctors and scientists. The company has also been working with manufacturing partners as it prepares for a wider rollout.
There is still no exact launch date or confirmed price. For now, the timeline is that pre-orders will open soon, with Goyal saying Temple will start shipping before the end of 2026.
